HCM vs. QGEN, ASND, ROIV, RVMD, BBIO, BPMC, ELAN, LEGN, TGTX, and TLX
Should you be buying HUTCHMED stock or one of its competitors? The main competitors of HUTCHMED include Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Legend Biotech (LEGN), TG Therapeutics (TGTX), and Telix Pharmaceuticals Limited American Depositary Shares (TLX). These companies are all part of the "pharmaceutical products" industry.
HUTCHMED vs.
HUTCHMED (NASDAQ:HCM) and Qiagen (NYSE:QGEN) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends.
HUTCHMED has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.
HUTCHMED received 65 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 66.11% of users gave HUTCHMED an outperform vote while only 60.19% of users gave Qiagen an outperform vote.
Qiagen has a net margin of 4.23% compared to HUTCHMED's net margin of 0.00%. Qiagen's return on equity of 13.92% beat HUTCHMED's return on equity.
8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 3.6% of HUTCHMED shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Qiagen had 18 more articles in the media than HUTCHMED. MarketBeat recorded 19 mentions for Qiagen and 1 mentions for HUTCHMED. Qiagen's average media sentiment score of 1.17 beat HUTCHMED's score of -0.11 indicating that Qiagen is being referred to more favorably in the news media.
HUTCHMED currently has a consensus target price of $19.00, suggesting a potential upside of 40.69%. Qiagen has a consensus target price of $48.42, suggesting a potential upside of 13.14%. Given HUTCHMED's higher possible upside, equities analysts plainly believe HUTCHMED is more favorable than Qiagen.
HUTCHMED has higher earnings, but lower revenue than Qiagen.
Summary
Qiagen beats HUTCHMED on 12 of the 16 factors compared between the two stocks.
Get HUTCHMED News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HUTCHMED Competitors List
Related Companies and Tools
This page (NASDAQ:HCM) was last updated on 5/21/2025 by MarketBeat.com Staff
